Cohance Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has submitted a quarterly compliance certificate to BSE and NSE for the quarter ended June 30, 2025. The certificate, issued by KFin Technologies (the company's Registrar and Share Transfer Agent), confirms that details of shares dematerialized and rematerialized during the quarter have been reported to both CDSL and NSDL depositories as well as the stock exchanges. This is a routine regulatory filing required under SEBI's depository regulations. There are no financial figures, business updates, or corporate actions disclosed in this filing.
No impact on shareholders or stock price. This is a standard procedural compliance filing that confirms routine share transfer/dematerialization reporting is up to date.